Diurnal Group PLC
http://www.diurnal.co.uk/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Diurnal Group PLC
Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Diurnal Renames Orphan Drug As Efmody, Expecting EU-Wide Approval
New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.
EU Crunch Time For Diurnal’s Potentially 'Transformational' Rare Disease Drug
The European Medicines Agency is deciding on the EU marketing application for Chronocort, a life-long treatment for congenital adrenal hyperplasia.
Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Diurnal Limited